Executive Committee

Guido Oelkers
Chief Executive Officer

Born 1965. Employed since 2017. PhD in Strategic Management, University of South Australia, Master of Economics, South Bank University, London, Complementary studies in Economics, London School of Economics and Political Science.

Other appointments: 

Previous positions: President and CEO, Gambro, CEO, Invida, a number of executive commercial operations roles in Nycomed, DKSH Group and Aventis, member of the Board of Directors at Meda.

Mats-Olof Wallin
Senior Vice President, Chief Financial Officer

Born 1951. Employed since 2013. B.Sc. at the University of Uppsala. 

Previous positions: More than 30 years of experience in the pharmaceutical industry, gained from various executive positions within companies such as Pharmacia, Ortivus and, most recently, Biotage AB (publ) where he held the role of CFO between 2003 and 2011. 

Carin Dahlquist
General Counsel and Head of Legal Affairs

Born 1974. Employed since 2015. Master of Laws from the University of Lund, Sweden and New York University School of Law, USA.

Previous positions: Senior Legal Counsel at GE Healthcare Life Sciences 2006 - 2015. Legal Counsel at Q-Med AB, 2005-2006. Law firm Linklaters 2001-2005.

Hege Hellstrom
Head of EMENAR

Born 1965. Employed since 2013. Bachelor in Bioengineering

Previous positions: Global head of Cardiovascular business unit in Sanofi, Vice President Renal Europe and Head of Regional Liaisons, Sanofi, Vice President Renal and Endocrine Europe, Genzyme, General Manager Benelux Genzyme. Prior to Genzyme 13 years in Baxter.

 

Rami Levin
Head of North America

Born 1969. Employed since 2014. MBA from Rekanati Business School, Tel-Aviv University, Israel . BSc in Biology - Tel-Aviv University, Israel.

Other appointments: Board of advisors of “Life Science Cares”, Corporate alliance member for Global Genes, Corporate council member for the National Organization for Rare Disorders (NORD), Regional chamber representative for the Swedish American Chamber of Commerce.

Previous positions: Various senior roles within Merck since 1998, most recently as Vice President of Marketing (US). Managing Director Scandinavia, Global Marketing Head, Business Unit Manager. Product Manager, Schering AG.

 

 

Norbert Oppitz
Head of Specialty Care

Born 1967. Employed since 2017. Dipl. BW (FH)/Business Administrator, FH Rhenania Palatina/Mainz, Germany

Previous positions: Member of the Executive Committee of BSN Medical in charge of Latin America. Member of the Executive Committee of Endo Pharmaceuticals, Emerging Markets. Head of Latin America, Takeda/Nycomed as well as country management roles at Roche Pharmaceuticals and Aventis Pharma.

Armin Reininger
Head of Medical and Scientific Affairs

Born 1957. Employed since 2017.  MD, PhD , Ludwig-Maximilians-University Munich, Germany; certified specialist in Transfusion Medicine

Previous positions: Baxter Head of Medical Affairs EMEA Hemophilia, Baxalta Head of Global Medical Affairs Hematology, Baxalta/Shire Head of Medical Affairs EMEA Hematology, Senior Physician University Clinic Munich, Dpt. of Transfusion Medicine and Haemostaseology. Visiting Scientist-Visiting Lecturer Harvard Medical School, Mass. General Hospital, Boston, MA, Visiting Fellow The Scripps Research Institute, La Jolla, CA, Professor of Anatomy at the Ludwig Maximilians-University Munich, Germany.

Philip Wood
Head of Haemophilia

Born 1968. Employed since 2012

BSc Joint Honours degree in Geology and Physical Geography, Charted Institute of Marketing certification.

Previous appointments: Head of European Strategic Asset team, Haemophilia, and Business Unit Head Haemophilia, UK, Pfizer.

Milan Zdravkovic
Head of Research & Development, Chief Medical Officer

Born: 1970. Employed since: 2016 MD, PhD University of Aarhus, Denmark, MSc Pharmaceutical Medicine, University of Surrey, United Kingdom

Other appointments: DIA Advisory Council Europe, Middle East and Africa. Board member and co-founder of Selma Diagnostics Aps

Previous positions: Corporate Vice President, Novo Nordisk. 18 year tenure in the Research and Development organisation at Novo Nordisk responsible for therapeutic areas including diabetes, devices, growth hormone deficiency, obesity and immunology. Experience from early stage drug development to post-approval life-cycle management.

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne